Induction of HIV-1 resistance: Cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels

Glycobiology

Volumn 19, Issue 1, 2009, Pages 76-82

  Ramkumar, Stephanie ^a,d   Sakac, Darinka ^b   Binnington, Beth ^d   Branch, Donald R ^a,b,c   Lingwood, Clifford A ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Glycosphingolipids; Gp120; Lipid rafts; pk blood group antigen

Indexed keywords

1 DEOXYGALACTONOJIRIMYCIN; 1 DEOXYNOJIRIMYCIN; ALPHA GALACTOSIDASE; ANTIGEN P24; CD4 ANTIGEN; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CHEMOKINE RECEPTOR CCR5; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; PHENYL 2 PALMITYLAMINO 3 PYRROLIDINO 1 PROPANOL; PROPANOL; UNCLASSIFIED DRUG; VEROTOXIN 1;

ARTICLE; CARBOHYDRATE ANALYSIS; CARBOHYDRATE METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INFECTION SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; THIN LAYER CHROMATOGRAPHY; VIRUS INDUCTION; VIRUS RESISTANCE;

CELL LINE, TUMOR; CELLS, CULTURED; FLOW CYTOMETRY; HIV-1; HUMANS; IMMUNITY, INNATE; TRIHEXOSYLCERAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 57649180469     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwn106     Document Type: Article

References (49)

1. Ablan S, Rawat SS, Viard M, Wang JM, Puri A, Blumenthal R. 2006. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion. Virol J. 3:104.
2. Bhat S, Mettus RV, Reddy EP, Ugen KE, Srikanthan V, Williams WV, Weiner DB. 1993. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275. AIDS Res Hum Retroviruses 9:175-181.
3. Boyd B, Zhiuyan Z, Magnusson G, Lingwood CA. 1994. Lipid modulation of glycolipid receptor function: Presentation of galactose α1-4 galactose disaccharide for verotoxin binding in natural and synthetic glycolipids. Eur J Biochem. 223:873-878.
4. Branch DR, Valenta LJE, Yousefi S, Sakac D, Singla R, Sahai BM, Bali M, Ma X-Z. 2002. VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively facilitates productive HIV-1 infection. AIDS. 16: 309-319.
5. Campbell SM, Crowe SM, Mak J. 2001. Lipid rafts and HIV-1: From viral entry to assembly of progeny virions. J Clin Virol. 22:217-227.
6. Cormier EG, Dragic T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol. 76:8953-8957.
7. Delezay O, Hammache D, Fantini J, Yahi N. 1996. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. Biochemistry. 35:15663-15671.
8. Delezay O, Yahi N, Tamalet C, Baghdiguian S, Boudier JA, Fantini J. 1997. Direct effect of type 1 human immunode.ciency virus (HIV-1) on intestinal epithelial cell differentiation: Relationship to HIV-1 enteropathy. Virology. 238:231-242.
9. Falguieres T, Mallard F, Baron C, Hanau D, Lingwood C, Goud B, Salamero J, Johannes L. 2001. Targeting of Shiga toxin b-subunit to retrograde transport route in association with detergent-resistant membranes. Mol Biol Cell. 12:2453-2468.
10. Fantini J. 2000. Synthetic soluble analogs of glycolipids for studies of virus-glycolipid interactions. Methods Enzymol. 311:626-638.
11. Fantini J, Hammache D, Delezay O, Pieroni G, Tamalet C, Yahi N. 1998. Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells. Virology. 246:211-220.
12. Fantini J, Hammache D, Pieroni G, Yahi N. 2000. Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion. Glycoconj J. 17: 199-204.
13. Hammache D, Piéroni G, Yahi N, Delézay O, Koch N, Lafont H, Tamalet C, Fantini J. 1998. Speci.c interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J Biol Chem. 273:7967-7971.
14. Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH, Gonzalez-Scarano F. 1991. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science. 253:320-323.
15. Hug P, Lin H, Korte T, Xiao X, Dimitrov D, Wang J, Puri A, Blumenthal R. 2000. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol. 74:6377-6385.
16. Jones PL, Korte T, Blumenthal R. 1998. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem. 273:404-409.
17. Khine AA, Lingwood CA. 2000. Functional significance of globotriaosylceramide in α2-interferon/type I interferon receptor mediated anti viral activity. J Cell Physiol. 182:97-108.
18. Lee L, Abe A, Shayman JA. 1999. Improved inhibitors of glucosylceramide synthase. J Biol Chem. 274:14662-14669.
19. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. 2001. Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses. 17:1009-1019.
20. Lingwood CA, Yiu SCK. 1992. Glycolipid modification of α2-interferon binding: Sequence similarity between α2-interferon receptor and the verotoxin (Shiga-like toxin) B-subunit. Biochem J. 283:25-26.
21. Lund N, Branch D, Mylvaganam M, Chark D, Ma X, Sakac D, Binnington B, Fantini J, Puri A, Blumenthal R, Lingwood C. 2006. A novel soluble mimic of the glycolipid globotriaosylceramide inhibits HIV infection. AIDS 20:1-11.
22. Lund N, Branch DR, Sakac D, Lingwood C, Siatskas C, Robinson C, Brady R, Medin J. 2005. Lack of susceptibility of cells from patients with Fabry disease to infection with R5 human immunodeficiency virus. AIDS. 19:1543-1546.
23. k blood group antigen.
24. Mahfoud R, Garmy N, Maresca M, Yahi N, Puigserver A, Fantini J. 2002. Identification of a common sphingolipid-binding domain in Alzheimer, prion and HIV-1 proteins. J Biol Chem. 277:11292-11296.
25. Mahfoud R, Manis A, Lingwood C. In press. Fatty acid-dependent globotriaosyl ceramide receptor function in detergent resistant model membranes. J Lip Res. Epub ahead of print August 20, 2008: Doi: 10.1194/jlr.M800385-JLR200.
26. 3 interaction. J Lipid Res. 43:1670-1679.
27. Manes S, Ana Lacalle R, Gomez-Mouton C, Martinez AC. 2003. From rafts to crafts: Membrane asymmetry in moving cells. Trends Immunol. 24:320-326.
28. Manes S, del Real G, Lacalle RA, Lucas P, Gomez-Mouton C, Sanchez-Palomino S, Delgado R, Alcami J, Mira E, Martinez-A C. 2000. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Reports. 1:190-196.
29. Manes S, Lacalle R, Gomez-Mouton C, del Real G, Mira E, Martinez-A C. 2001. Membrane raft microdomains in chemokine receptor function. Sem Immunol. 13:147-157.
30. Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J. 1991. CD77: An antigen of germinal center B cells entering apoptosis. Eur J Immunol 21:1131-1140.
31. Mylvaganam M, Lingwood CA. 1999. A convenient oxidation of natural glycosphingolipids to their "ceramide acids" for neoglycoconjugation: Bovine serum albumin-glycoceramide acid conjugates as investigative probes for HIV coat protein gp120-glycosphingolipid interactions. J Biol Chem. 274:20725-20732.
32. Nguyen DH, Giri B, Collins G, Taub DD. 2005. Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement. Exp Cell Res. 304:559-569.
33. Nguyen DH, Hildreth JE. 2000. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol. 74:3264-3272.
34. Nutikka A, Binnington-Boyd B, Lingwood C. 2003. Methods for the identification of host receptors for Shiga toxin. In: Philpot D, Ebel F, editors. Methods in Molecular Medicine. Totowa (NY): Humana. p. 197-208.
35. Puri A, Hug P, Jernigan K, Barchi J, Kim H-Y, Hamilton J, Wiels J, Murray GJ, Brady RO, Blumenthal R. 1998a. The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc Natl Acad Sci 95:14435-14440.
36. + cells. Biochem Biophys Res Commun. 242:219-225.
37. Puri A, Hug P, Munoz-Berroso I, Blumenthal R. 1999. Role of glycosphingolipids in HIV-1 entry: Requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. Biosci Rep. 19:317-325.
38. Rawat SS, Eaton J, Gallo SA, Martin TD, Ablan S, Ratnayake S, Viard M, KewalRamani VN, Wang JM, Blumenthal R, Puri A. 2004. Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion. Virology. 318:55-65.
39. Rawat SS, Gallo SA, Eaton J, Martin TD, Ablan S, KewalRamani VN, Wang JM, Blumenthal R, Puri A. 2004. Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion. J Virol. 78:7360-7368.
40. Rawat SS, Zimmerman C, Johnson BT, Cho E, Lockett SJ, Blumenthal R, Puri A. 2008. Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion. Mol Membr Biol. 25:83-94.
41. Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T. 1998. T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol. 72:9763-9770.
42. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med. 186:1383-1388.
43. Sorice M, Garofalo T, Misasi R, Longo A, Mattei V, Sale P, Dolo V, Gradini R, Pavan A. 2001. Evidence for cell surface association between CXCR4 and ganglioside GM3 after gp120 binding in SupT1 lymphoblastoid. cells. FEBS Lett. 506:55-60.
44. Sorice M, Parolini I, Sansolini T, Garofalo T, Dolo V, Sargiacomo M, Tai T, Peschle C, Torrisi MR, Pavan A. 1997. Evidence for the existence of ganglioside-enriched plasma membrane domains in human peripheral lymphocytes. J Lipid Res. 38:969-980.
45. Spitalnik P, Spitalnik S. 1995. The P blood group system: Biochemical, serological and clinical aspects. Transfus Med Rev. 9:110-122.
46. Ullrich R, Schmidt W, Zippel T, Schneider T, Zeitz M, Riecken EO. 1998. Mucosal HIV infection. Pathobiol. 66:145-150.
47. Viard M, Parolini I, Rawat SS, Fecchi K, Sargiacomo M, Puri A, Blumenthal R. 2004. The role of glycosphingolipids in HIV signaling, entry and pathogenesis. Glycoconj J. 20:213-222.
48. Xiao L, Owen SM, Goldman I, Lal AA, deJong JJ, Goudsmit J, Lal RB. 1998. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology. 240:83-92.
49. Yeaman GR, Howell AL, Weldon S, Demian DJ, Collins JE, O'Connell DM, Asin SN, Wira CR, Fanger MW. 2003. Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: Regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology. 109:137-146.